Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Bezafibrate (400MG) IN addition TO standard 15-20 MG/KG/jour udca therapy[2] Bezafibrate,
Ursodeoxycholic acid (UDCA)		[2] Ursodiol ,
Bezafibrate 💬 		[2] NR1C1,
NR1H4 💬 		[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 94 💬
2Bezafibrate 200 MG IN addition TO udca therapy[2] Bezafibrate,
Ursodeoxycholic acid (UDCA)		[2] Ursodiol ,
Bezafibrate 💬 		[2] NR1C1,
NR1H4 💬 		[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
3Bezafibrate 400 MG IN addition TO udca therapy[2] Bezafibrate,
Ursodeoxycholic acid (UDCA)		[2] Ursodiol ,
Bezafibrate 💬 		[2] NR1C1,
NR1H4 💬 		[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
4Standard OF care: udca----[1] 93 💬
5Udca[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[5] 67, 93, 94, 97, 296 💬
6Ursodeoxycholic acid (udca) 500 MG[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[1] 46 💬